Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019

Multiple Sclerosis Clinical Trial

— EXTEND  

Official title:

A Multicenter, Open-Label, Extension Study to Evaluate the Long Term Safety and Efficacy of BIIB019, Daclizumab High Yield Process (DAC HYP), Monotherapy in Subjects With Multiple Sclerosis Who Have Completed Study 205MS301

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01797965
• Other study ID #: 205MS303
• Secondary ID: 2012-003176-39
• Status: Terminated
• Phase: Phase 3
• Start date: February 15, 2013
• Est. completion date: September 24, 2018

Study information

• Verified date: November 2019
• Source: Biogen
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective of the study is to assess the safety and tolerability of long-term treatment with BIIB019 (Daclizumab High Yield Process; DAC HYP) monotherapy in participants with relapsing remitting multiple sclerosis (RRMS) who completed Study 205MS301 (NCT01064401), Study 205MS203 (NCT01051349) or Study 205MS302 (NCT01462318).

Secondary objectives of this study in this study population are as follows:

To describe MS-related outcomes, including MS relapse, disability progression, MS lesion formation, and participant-reported impact of MS, following long-term treatment with DAC HYP To assess the long-term immunogenicity of DAC HYP administered by prefilled syringe (PFS) To assess the safety, tolerability, and efficacy of switching to DAC HYP in participants previously on long-term treatment with interferon β-1a (Avonex) in Study 205MS301(NCT01064401).

Description:

Enrollment will include up to 1600 Participants, this includes approximately 1200 Participants who completed Study 205MS301 (NCT01064401). Additionally, approximately 400 Participants from the other BIIB019 extension studies 205MS203 (NCT01051349) and 205MS302 (NCT01462318) will be eligible to enter Study 205MS303 at Week 144 of Study 205MS303 [Study 205MS301 (NCT01064401), study 205MS203 (NCT01051349) and study 205MS302 (NCT01462318) have been referred to as parent studies in the protocol]. All Participants will receive the same dose of DAC HYP as received in the parent studies; i.e., 150 mg by an SC injection every 4 weeks.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 1501
• Est. completion date: September 24, 2018
• Est. primary completion date: September 24, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Key Inclusion Criteria:

• Must be a subject currently participating in Study 205MS301 (NCT01064401), or subject currently participating in Study 205MS203 (NCT01051349) or Study 205MS302 (NCT01462318) who has completed End of Study Visit (Week 96 or later).

• Women of childbearing potential must practice effective contraception during the study and be willing and able to continue contraception for 4 months after their last dose of study treatment.

Key Exclusion Criteria:

• Any subject who permanently discontinued study treatment in Study 205MS301 (NCT01064401), Study 205MS203 (NCT01051349) or Study 205MS302 (NCT01462318) prior to the end of the study treatment period, or had an Early Termination visit in Study 205MS301, Study 205MS203 (NCT01051349) or Study 205MS302 (NCT01462318).

• Any significant change in the subject's medical history that would preclude administration of BIIB019, including laboratory tests or a current clinically significant condition that, in the opinion of the Investigator, would have excluded the subject's participation in Study 205MS301 (NCT01064401), Study 205MS203 (NCT01051349) or Study 205MS302 (NCT01462318).

The Investigator must re review the subject's medical fitness for participation and consider any factors that would preclude treatment in this Study 205MS303.

NOTE: Other protocol-defined inclusion/exclusion criteria may apply.

Related Conditions & MeSH terms

• Multiple Sclerosis
• Multiple Sclerosis, Relapsing-Remitting
• Relapsing-Remitting Multiple Sclerosis
• Sclerosis

Intervention

Drug:
• BIIB019 (Daclizumab)
Participants will receive open-label treatment with BIIB019 150 mg subcutaneous injection every 4 weeks for up to 5 years.

Locations

Country	Name	City	State
Argentina	Research Site	Ciudad Autónoma de Buenos Aires	Buenos Aires
Argentina	Research Site	Ciudad Autónoma de Buenos Aires	Buenos Aires
Argentina	Research Site	Godoy Cruz	Mendoza
Argentina	Research Site	Rosario	Santa Fe
Australia	Research Site	Auchenflower	Queensland
Australia	Research Site	Heidelberg	Victoria
Brazil	Research Site	Belo Horizonte	Minas Gerais
Brazil	Research Site	Campinas	São Paulo
Brazil	Research Site	Porto Alegre	Rio Grande Do Sul
Brazil	Research Site	Recife	Pernambuco
Brazil	Research Site	Ribeirão Preto	São Paulo
Brazil	Research Site	Rio de Janeiro
Brazil	Research Site	Rio De Janeiro
Canada	Research Site	Gatineau	Quebec
Canada	Research Site	Greenfield Park	Quebec
Canada	Research Site	London	Ontario
Canada	Research Site	Ottawa	Ontario
Canada	Research Site	Saint Johns	Newfoundland and Labrador
Canada	Research Site	Vancouver	British Columbia
Czechia	Research Site	Brno	Jihomoravský Kraj
Czechia	Research Site	Brno	Jihomoravský Kraj
Czechia	Research Site	Hradec Kralove
Czechia	Research Site	Jihlava	Kray Vysocina
Czechia	Research Site	Olomouc	Severomoravsky Kraj
Czechia	Research Site	Ostrava	Moravskoslezský Kraj
Czechia	Research Site	Pardubice	Pardubický Kraj
Czechia	Research Site	Praha 10	Praha
Czechia	Research Site	Praha 2	Praha
Czechia	Research Site	Praha 5
Czechia	Research Site	Teplice	Ústecký Kraj
Denmark	Research Site	Copenhagen
Denmark	Research Site	Glostrup
Denmark	Research Site	Odense C
France	Research Site	Amiens Cedex 1
France	Research Site	Bobigny	Ile-de-France
France	Research Site	Bordeaux	Gironde
France	Research Site	Caen	Calvados
France	Research Site	Lille	Nord
France	Research Site	Marseille	Bouches-du-Rhône
France	Research Site	Nancy	Meurthe-et-Moselle
France	Research Site	Paris
France	Research Site	Strasbourg	Bas-Rhin
France	Research Site	Toulouse	Haute-Garonne
Georgia	Research Site	Tbilisi
Germany	Research Site	Bad Mergentheim	Baden-Württemberg
Germany	Research Site	Bamberg
Germany	Research Site	Bayreuth	Bayern
Germany	Research Site	Dresden	Sachsen
Germany	Research Site	Erlangen	Bayern
Germany	Research Site	Freiburg	Baden-Württemberg
Germany	Research Site	Marburg	Hessen
Germany	Research Site	München	Bayern
Germany	Research Site	Rostock	Mecklenburg-Vorpommern
Greece	Research Site	Athens	Attiki
Greece	Research Site	Athens
Greece	Research Site	Thessaloniki
Greece	Research Site	Thessaloniki	Macedonia
Hungary	Research Site	Balatonfüred
Hungary	Research Site	Budapest
Hungary	Research Site	Budapest
Hungary	Research Site	Budapest
Hungary	Research Site	Budapest
Hungary	Research Site	Debrecen
Hungary	Research Site	Esztergom
Hungary	Research Site	Gyor
Hungary	Research Site	Kecskemét	Bács-Kiskun
Hungary	Research Site	Miskolc
Hungary	Research Site	Miskolc	Borsod-Abaúj-Zemplén
Hungary	Research Site	Nyíregyháza
Hungary	Research Site	Székesfehérvár	Fejer
India	Research Site	Bangalore	Karnataka
India	Research Site	Gurgaon
India	Research Site	Hyderabad	Andhra Pradesh
India	Research Site	Mumbai	Maharashtra
India	Research Site	Trivandrum	Kerala
Ireland	Research Site	Dublin
Ireland	Research Site	Dublin
Israel	Research Site	Ashkelon
Israel	Research Site	Haifa
Israel	Research Site	Petah Tikva
Israel	Research Site	Safed
Italy	Research Site	Catania
Italy	Research Site	Cefalù
Italy	Research Site	Genova	Liguria
Italy	Research Site	Milano	Lombardia
Italy	Research Site	Padova	Veneto
Italy	Research Site	Roma
Italy	Research Site	Roma
Mexico	Research Site	Distrito Federal
Mexico	Research Site	Distrito Federal
Moldova, Republic of	Research Site	Chisinau
Moldova, Republic of	Research Site	Chisinau
Poland	Research Site	Bialystok	Podlaskie
Poland	Research Site	Bialystok	Podlaskie
Poland	Research Site	Bydgoszcz	Kujawsko-pomorskie
Poland	Research Site	Gdansk	Pomorskie
Poland	Research Site	Gdansk	Pomorskie
Poland	Research Site	Gdansk
Poland	Research Site	Grudziadz
Poland	Research Site	Katowice
Poland	Research Site	Katowice
Poland	Research Site	Katowice	Slaskie
Poland	Research Site	Katowice	Slaskie
Poland	Research Site	Katowice	Slaskie
Poland	Research Site	Kielce	Swietokrzyskie
Poland	Research Site	Kraków	Malopolskie
Poland	Research Site	Kraków	Malopolskie
Poland	Research Site	Lodz	Lódzkie
Poland	Research Site	Lublin	Lubelskie
Poland	Research Site	Olsztyn	Warminsko-mazurskie
Poland	Research Site	Olsztyn
Poland	Research Site	Plewiska	Wielkopolskie
Poland	Research Site	Poznan	Wielkopolskie
Poland	Research Site	Poznan	Wielkopolskie
Poland	Research Site	Poznan	Wielkopolskie
Poland	Research Site	Szczecin	Zachodniopomorskie
Poland	Research Site	Szczecin	Zachodniopomorskie
Poland	Research Site	Warszawa	Mazowieckie
Poland	Research Site	Warszawa	Mazowieckie
Poland	Research Site	Warszawa	Mazowieckie
Poland	Research Site	Warszawa	Mazowieckie
Poland	Research Site	Warszawa	Mazowieckie
Romania	Research Site	Bucharest
Romania	Research Site	Cluj- Napoca	Cluj
Romania	Research Site	Iasi
Romania	Research Site	Târgu Mures	Mures
Romania	Research Site	Timisoara	Timis
Russian Federation	Research Site	Kazan
Russian Federation	Research Site	Kemerovo
Russian Federation	Research Site	Krasnoyarsk
Russian Federation	Research Site	Moscow
Russian Federation	Research Site	Moscow
Russian Federation	Research Site	Nizhny Novgorod
Russian Federation	Research Site	Nizhny Novgorod
Russian Federation	Research Site	Novosibirsk
Russian Federation	Research Site	Omsk
Russian Federation	Research Site	Perm
Russian Federation	Research Site	Samara
Russian Federation	Research Site	Smolensk
Russian Federation	Research Site	St. Petersburg
Russian Federation	Research Site	St. Petersburg
Russian Federation	Research Site	St. Petersburg
Russian Federation	Research Site	Tyumen
Russian Federation	Research Site	Ufa
Russian Federation	Research Site	Yaroslavl	Yaroslavlr
Serbia	Research Site	Belgrade
Serbia	Research Site	Kragujevac
Serbia	Research Site	Nis
Serbia	Research Site	Novi Sad
Spain	Research Site	Badalona	Barcelona
Spain	Research Site	Cordoba	Córdoba
Spain	Research Site	Girona
Spain	Research Site	l'Hospitalet de Llobregat
Spain	Research Site	Madrid	Madrid, Communidad Delaware
Spain	Research Site	Sevilla
Sweden	Research Site	Göteborg	Vastra Gotalands Lan
Sweden	Research Site	Malmö	Skane
Sweden	Research Site	Stockholm	Sodermanlands Lan
Sweden	Research Site	Stockholm	Sodermanlands Lan
Sweden	Research Site	Stockholm
Switzerland	Research Site	Basel	Basel-Stadt (de)
Ukraine	Research Site	Chernivtsi	Chernivets'ka Oblast
Ukraine	Research Site	Dnipropetrovsk	Dnipropetrovs'ka Oblast'
Ukraine	Research Site	Donetsk	Donets'ka Oblast'
Ukraine	Research Site	Kharkiv	Kharkivs'ka Oblast'
Ukraine	Research Site	Kharkiv
Ukraine	Research Site	Kyiv	Kyïv
Ukraine	Research Site	Kyiv	Kyïv
Ukraine	Research Site	Kyiv	Kyïv
Ukraine	Research Site	Odesa	Odes'ka Oblast
Ukraine	Research Site	Poltava	Poltavs'ka Oblast
Ukraine	Research Site	Vinnytsia	Vinnyts'ka Oblast'
Ukraine	Research Site	Zaporizhzhia	Zaporiz'ka Oblast'
Ukraine	Research Site	Zaporizhzhia	Zaporizhia Oblast
United Kingdom	Research Site	Brighton
United Kingdom	Research Site	Edinburgh	Edinburgh, City Of
United Kingdom	Research Site	London
United Kingdom	Research Site	London
United Kingdom	Research Site	London
United Kingdom	Research Site	London
United Kingdom	Research Site	Nottingham
United Kingdom	Research Site	Plymouth	Devon
United Kingdom	Research Site	Sheffield
United States	Research Site	Albuquerque	New Mexico
United States	Research Site	Allentown	Pennsylvania
United States	Research Site	Atlanta	Georgia
United States	Research Site	Aurora	Colorado
United States	Research Site	Buffalo	New York
United States	Research Site	Centennial	Colorado
United States	Research Site	Charlotte	North Carolina
United States	Research Site	Cordova	Tennessee
United States	Research Site	Dayton	Ohio
United States	Research Site	Farmington Hills	Michigan
United States	Research Site	Fort Wayne	Indiana
United States	Research Site	Franklin	Tennessee
United States	Research Site	Henrico	Virginia
United States	Research Site	Indianapolis	Indiana
United States	Research Site	Kansas City	Kansas
United States	Research Site	Knoxville	Tennessee
United States	Research Site	La Jolla	California
United States	Research Site	Latham	New York
United States	Research Site	Lebanon	New Hampshire
United States	Research Site	Lexington	Kentucky
United States	Research Site	Little Rock	Arkansas
United States	Research Site	Medford	Oregon
United States	Research Site	Milwaukee	Wisconsin
United States	Research Site	Naples	Florida
United States	Research Site	New York	New York
United States	Research Site	New York	New York
United States	Research Site	Phoenix	Arizona
United States	Research Site	Phoenix	Arizona
United States	Research Site	Pittsburgh	Pennsylvania
United States	Research Site	Pompano Beach	Florida
United States	Research Site	Portland	Oregon
United States	Research Site	Raleigh	North Carolina
United States	Research Site	Rochester	New York
United States	Research Site	Round Rock	Texas
United States	Research Site	Tacoma	Washington
United States	Research Site	Tucson	Arizona
United States	Research Site	Wellesley	Massachusetts
United States	Research Site	Winston-Salem	North Carolina
United States	Research Site	Worcester	Massachusetts

Sponsors (2)

Lead Sponsor	Collaborator
Biogen	AbbVie

Countries where clinical trial is conducted

United States,  Argentina,  Australia,  Brazil,  Canada,  Czechia,  Denmark,  France,  Georgia,  Germany,  Greece,  Hungary,  India,  Ireland,  Israel,  Italy,  Mexico,  Moldova, Republic of,  Poland,  Romania,  Russian Federation,  Serbia,  Spain,  Sweden,  Switzerland,  Ukraine,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)	An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product; it does not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product. A SAE is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria.	First dose of study drug in Study 303 to within 180 days of last dose (up to approximately 5.5 years)
Secondary	Annualized Relapse Rate (ARR) in the 205MS303 Treatment Period	Relapses are defined as new or recurrent neurological symptoms not associated with fever or infection, lasting at least 24 hours, and accompanied by new objective neurological findings upon examination by the Study Neurologist. The unadjusted ARR was calculated by tabulating the total number of relapses experienced in the group divided by the number of days up to the end of study, and the ratio then multiplied by 365.25. Relapses that occurred after participants received alternative multiple sclerosis (MS) medications were excluded from the analyses. ARR was adjusted for relapse rate, IFN beta use, Expanded Disability Status Scale (EDSS) (<=2.5 vs >2.5) and age (<=35 vs >35) prior to start of study treatment in 205MS301, calculated using the negative binomial model.	Up to 4.6 years in the 303 study
Secondary	ARR in the 205MS301-303 Combined Study Period and 205MS301 Treatment Period	Relapses are defined as new or recurrent neurological symptoms not associated with fever or infection, lasting at least 24 hours, and accompanied by new objective neurological findings upon examination by the Study Neurologist. The unadjusted ARR was calculated by tabulating the total number of relapses experienced in the group divided by the number of days up to the end of study, and the ratio then multiplied by 365.25. Relapses that occurred after participants received alternative MS medications were excluded from the analyses. ARR was adjusted for relapse rate, IFN beta use, EDSS (<=2.5 vs >2.5) and age (<=35 vs >35) prior to start of study treatment in 301, calculated using the negative binomial model.	Up to 5.6 years combining 303 with the initial Study 301; Up to 1 year in the 301 study
Secondary	Number of Participants With Relapse in the 205MS303 Treatment Period	Relapses are defined as new or recurrent neurological symptoms not associated with fever or infection, lasting at least 24 hours, and accompanied by new objective neurological findings upon examination by the Study Neurologist.	Up to 4.6 years in the 303 study
Secondary	Number of Participants With Relapse in the 205MS301-303 Combined Study Period	Relapses are defined as new or recurrent neurological symptoms not associated with fever or infection, lasting at least 24 hours, and accompanied by new objective neurological findings upon examination by the Study Neurologist.	Up to 5.6 years combining 303 with the initial Study 301
Secondary	Number of Participants With Sustained Disability Progression in the 205MS303 Treatment Period	Sustained disability progression is defined as at least a 1.0-point increase on the Expanded Disability Status Scale (EDSS) from 303 baseline EDSS =1.0 that is sustained for 24 weeks, or at least a 1.5-point increase on the EDSS from 303 baseline EDSS of 0, that is sustained for 24 weeks. The EDSS measures the disability status of people with multiple sclerosis on a scale that ranges from 0 to 10. The range of main categories include (0) =normal neurologic exam; to (5) = ambulatory without aid or rest for 200 meters; disability severe enough to impair full daily activities; to (10) = death due to MS. Higher scores indicate more disability.	Up to 4.6 years in Study 303
Secondary	Number of Participants With Sustained Disability Progression in the 205MS301-303 Combined Study Period	Sustained disability progression is defined as at least a 1.0-point increase on the Expanded Disability Status Scale (EDSS) from 303 baseline EDSS =1.0 that is sustained for 24 weeks, or at least a 1.5-point increase on the EDSS from 303 baseline EDSS of 0, that is sustained for 24 weeks. The EDSS measures the disability status of people with multiple sclerosis on a scale that ranges from 0 to 10. The range of main categories include (0) =normal neurologic exam; to (5) = ambulatory without aid or rest for 200 meters; disability severe enough to impair full daily activities; to (10) = death due to MS. Higher scores indicate more disability.	Up to 5.6 years combining 303 with the initial Study 301
Secondary	Number of Participants With New or Newly Enlarging T2 Hyperintense Lesions in the 205MS303 Treatment Period	T2 Hyperintense Lesions were assessed by magnetic resonance imaging (MRI) and were analyzed by a central MRI reader. The number of participants with New or Newly Enlarging T2 Hyperintense Lesions relative to the 303 Baseline in the 303 Treatment Period is reported.	Baseline 303, Weeks 48, 96, 144, 192, 240 in Study 303
Secondary	Number of Participants With New or Newly Enlarging T2 Hyperintense Lesions in the 205MS301 Treatment Period	T2 Hyperintense Lesions were assessed by MRI and were analyzed by a central MRI reader. The number of participants with New or Newly Enlarging T2 Hyperintense Lesions relative to the 301 Baseline in the 301 Treatment Period is reported.	Baseline 301, Weeks 24, 96, 144 in Study 301
Secondary	Number of Participants With Gadolinium-enhancing (Gd+) Lesions in the 205MS303 Treatment Period	Gd+ lesions were evaluated by MRI and were analyzed by a central MRI reader.	301-303: Baseline 303, Weeks 48, 96, 144, 192, 240; 203-303 and 302-303: Week 96
Secondary	Number of Participants With Gadolinium-enhancing (Gd+) Lesions in the 205MS301 Treatment Period	Gd+ lesions were evaluated by MRI and were analyzed by a central MRI reader.	Baseline 301, Weeks 24, 96 and 144
Secondary	Number of Participants With New T1 Hypointense Lesions in the 205MS303 Treatment Period	T1 hypointense lesions were evaluated by MRI and were analyzed by a central MRI reader. The number of participants with New T1 Hyperintense Lesions relative to the 303 Baseline in the 303 Treatment Period is reported.	Baseline 303, Weeks 48, 96, 144, 192, 240 in Study 303
Secondary	Number of Participants With New T1 Hypointense Lesions in the 205MS301 Treatment Period	T1 hypointense lesions were evaluated by MRI and were analyzed by a central MRI reader. The number of participants with New T1 Hyperintense Lesions relative to the 301 Baseline in the 301 Treatment Period is reported .	Baseline 301, Weeks 24, 96, 144 in Study 301
Secondary	Percent Change in Brain Volume From the 205MS303 Baseline	To assess brain atrophy, total brain volume was measured by MRI and was analyzed by a central MRI reader. A negative percent change from baseline indicates improvement.	Baseline 303, Weeks 48, 96, 144, 192, 240 in Study 303
Secondary	Percent Change in Brain Volume From 205MS301 Baseline	To assess brain atrophy, total brain volume was measured by MRI and was analyzed by a central MRI reader. A negative percent change from baseline indicates improvement.	Baseline 301, Weeks 48, 96, 144, 192, 240 in Study 303
Secondary	Total Volume of T2 Hyperintense Lesions in the 205MS303 Treatment Period	Volume of T2 hyperintense Lesions was evaluated by MRI and was analyzed by a central MRI reader.	Baseline 303, Weeks 48, 96, 144, 192, 240 in Study 303; 203-303 and 302-303: Week 96
Secondary	Change From Baseline in the Multiple Sclerosis Functional Composite (MSFC) Score in the 205MS303 Treatment Period	MSFC is a three-part, standardized, quantitative, assessment instrument consisting of (Timed 25-Foot Walk, Nine-Hole Peg Test (9HPT) and Paced Auditory Serial Addition Test (PASAT-3"). 2 timed 25-foot walk scores are averaged. 4 trials of the Peg Test (2 for each hand) are converted to the reciprocals and averaged. The number correct of the PASAT-3 is used. The composite Z-score is calculated by: Z(25-foot walk) + Z (HPT) + Z(PASAT)/3. A positive change from baseline indicates improvement.	Baseline 303, Weeks 12, 24 and 48 in Study 303
Secondary	Change From 205MS301 Baseline in the MSFC Score in the 205MS301-303 Combined Study Period	MSFC is a three-part, standardized, quantitative, assessment instrument consisting of (Timed 25-Foot Walk, Nine-Hole Peg Test (9HPT) and Paced Auditory Serial Addition Test (PASAT-3"). 2 timed 25-foot walk scores are averaged. 4 trials of the Peg Test (2 for each hand) are converted to the reciprocals and averaged. The number correct of the PASAT-3 is used. The composite Z-score is calculated by: Z(25-foot walk) + Z (HPT) + Z(PASAT)/3. A positive change from baseline indicates improvement.	Baseline 301, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 in the 301 study, Baseline 303, Weeks 12, 24, 48 in the 303 study
Secondary	Change From Baseline in the Expanded Disability Status Scale (EDSS) Score in the 205MS303 Treatment Period	The EDSS measures the disability status of people with multiple sclerosis as assessed by the Study Neurologist based on 8 functional systems that ranges from 0=normal neurologic exam; to 5=ambulatory without aid or rest for 200 meters; disability severe enough to impair full daily activities; to 10=death due to MS. Higher scores indicate more disability. A negative change from Baseline indicates improvement.	301-303: Baseline 303, Weeks 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 260; 203-303 and 302-303: Baseline 303, Weeks 12, 24, 48, 72, 96, 116 in Study 303
Secondary	Number of Participants Who Are Free From Disease Activity in the 205MS303 Treatment Period	Participants without clinical or radiological activity are defined as disease-free. Clinical activity includes assessment of relapses and of disease progression. Radiological activity includes assessments of Gd+ lesions and new or enlarging T2 lesions.	Up to 4.6 years in Study 303
Secondary	Change From Baseline in the Multiple Sclerosis Impact Scale 29 (MSIS 29) Physical and Psychological Scores in the 205MS303 Treatment Period	The 29-item MSIS-29 is a disease specific participant-reported outcome measure that has been developed and validated to examine the physical (coordination and mobility) and psychological (mental) impact of MS from a participant's perspective; it measures 20 physical items and 9 psychological items. The results for each of the physical and psychological scores are transformed to a score of 0 to 100 (worse state of health). A negative change from Baseline indicates improvement.	Baseline 303, Weeks 12, 24, 48, 96, 120 and 144
Secondary	Change From Baseline in Quality of Life as Assessed by the European Quality of Life, 5 Dimensions (EQ 5D) Health Scores in the 205MS303 Treatment Period	The EQ-5D is a self-administered questionnaire consisting of 5 domains pertaining to specific health state profile : mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The participants recorded their level of current health for each domain where: 1=no problems, 2=some problem and 3=severe problems. The health score is derived from the individual scores for each of the 5 domains transformed to a score of 0=worst health state to 1=perfect health state. A positive change from Baseline indicates improvement.	301-303: Baseline 303, Weeks 12, 24, 48, 96, 120, 144, 192, 240; 203-303 and 302-303: Baseline 303, Weeks 48 and 96 in Study 303
Secondary	Change From Baseline in Quality of Life as Assessed by the European Quality of Life, Visual Analog Scale (EQ VAS) in the 205MS303 Treatment Period	The participant rated their current heath state using the EQ VAS 20-centimeter horizontal line from 0 (worst imaginable health state) to 100 (best imaginable health state). A positive change from baseline indicates improvement.	301-303: Baseline 303, Weeks 12, 24, 48, 96, 120, 44, 192, 240; 203-303 and 302-303: Baseline 303, Weeks 48 and 96 in Study 303
Secondary	Direct Health Resource Utilization (HRU): Number of Unscheduled Site Visits in the 205MS303 Treatment Period	Heath resource utilization was assessed by the number of hospitalizations, emergency room visits, and unscheduled neurologist visits for MS-related and non-MS-related visits.	301-303: Baseline 303, Weeks 24, 48, 96, 144, 192, 240; 203-303 and 302-303: Baseline 303, Weeks 48, 96 in 303
Secondary	Direct Health Resource Utilization (HRU): Number of Unscheduled Site Visits in the 205MS301 Treatment Period	Heath resource utilization was assessed by the number of hospitalizations, emergency room visits, and unscheduled neurologist visits for MS-related and non-MS-related visits.	Baseline 301, Weeks 24, 48, 72, 96, 120 and 144 in 301
Secondary	Treatment Satisfaction as Assessed by the Participant in the 205MS303 Treatment Period	Participants answered the question: "How satisfied or dissatisfied are you with the ability of the medication to prevent or treat the condition?" using the following scale: Dissatisfied (Extremely dissatisfied, Very dissatisfied, Dissatisfied) or Satisfied (Somewhat satisfied, Satisfied, Very Satisfied and Extremely satisfied). The number of participants in the Dissatisfied and Satisfied categories is reported.	Baseline 303, Weeks 12, 24, 48, 72, 96, 120 in Study 303
Secondary	Health Related Productivity Questionnaire (HRPQ): Scheduled Work Hours in the 205MS303 Treatment Period	The HRPQ was used by the participant to assess the impact of MS or its treatments on employment. The participant recorded their scheduled work hours. Data is reported by part time or full time employment.	301-303: Baseline 303, Weeks 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240; 203-303 and 302-303: Baseline 303, Weeks 24, 48, 72, 96 in Study 303
Secondary	HRPQ: Number of Participants Where MS or Its Treatments Resulted in Missed Work in the 205MS303 Treatment Period	The HRPQ was used by the participant to assess the impact of MS or its treatments on employment. The participant recorded whether their MS or its treatments caused them to miss work. Data is reported by part time or full time employment.	301-303: Baseline 303, Weeks 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240; 203-303 and 302-303: Baseline 303, Weeks 24, 48, 72, 96 in Study 303
Secondary	HRPQ: Hours of Work Missed Due to MS or Its Treatment in the 205MS303 Treatment Period	The HRPQ was used by the participant to assess the impact of MS or its treatments on employment. The participant recorded the hours they missed work due to MS or its treatments. Data is reported by part time or full time employment.	301-303: Baseline 303, Weeks 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240; 203-303 and 302-303: Baseline 303, Weeks 24, 48, 72, 96 in Study 303
Secondary	HRPQ: Percent Impact on Employment in the 205MS303 Treatment Period	The HRPQ was used by the participant to assess the impact of MS or its treatments on employment. The participants assessed the percent impact of MS and its treatments on their work output using a VAS where 0= MS or its treatments had no impact on how much I accomplished to 100=MS or its treatments kept me from accomplishing anything. Data is reported for part time or full time employment.	301-303: Baseline 303, Weeks 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240; 203-303 and 302-303: Baseline 303, Weeks 24, 48, 72, 96 in Study 303
Secondary	HRPQ: Hours of Household Chores Planned to Perform in the 205MS303 Treatment Period	The HRPQ was used by the participant to assess the impact of MS or its treatments on performing household chores. The participant recorded their planned hours for household chores.	301-303: Baseline 303, Weeks 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240; 203-303 and 302-303: Baseline 303, Weeks 24, 48, 72, 96 in Study 303
Secondary	HRPQ: Number of Participants Where MS or Its Treatments Kept the Participant From Completing Chores in the 205MS303 Treatment Period	The HRPQ was used by the participant to assess the impact of MS or its treatments on performing household chores. The participant recorded whether MS or its treatments kept them from completing household chores.	301-303: Baseline 303, Weeks 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240; 203-303 and 302-303: Baseline 303, Weeks 24, 48, 72, 96 in Study 303
Secondary	HRPQ: Hours Not Performing Household Chores Due to MS or Its Treatment in 205MS303 Treatment Period	The HRPQ was used by the participant to assess the impact of MS or its treatments on performing household chores. The participant recorded the hours where they were not able to perform household chores due to MS or its treatments.	301-303: Baseline 303, Weeks 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240; 203-303 and 302-303: Baseline 303, Weeks 24, 48, 72, 96 in Study 303
Secondary	HRPQ: Percent Impact on Performing Household Chores in the 205MS303 Treatment Period	The HRPQ was used by the participant to assess the impact of MS or its treatments on performing household chores. The participant assessed the percent impact of MS and its treatments on how much they accomplished using a VAS where 0= MS or its treatments had no impact on how much I accomplished to 100=MS or its treatments kept me from accomplishing anything.	301-303: Baseline 303, Weeks 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240; 203-303 and 302-303: Baseline 303, Weeks 24, 48, 72, 96 in Study 303
Secondary	Number of Participants With Clinically Significant Changes From Baseline in Clinical Laboratory Assessments in the 205MS303 Treatment Period	Clinical Laboratory assessments included tests of hematology, blood chemistry, renal function, and thyroid function. The investigator determined if the results were clinically significant.	Up to 4.6 years in 303
Secondary	Local Tolerability as Assessed by Participant-reported Injection Site Pain VAS	The VAS is a 10 cm-long horizontal line labeled with 2 extremes of pain at either end: 0 =no pain on the left and 100=very painful on the right. The participant rates their perceived pain of each injection by placing a vertical mark on the line to indicate the level of pain.	After the first and fourth injections in 303, approximately Week 0 and Week 12
Secondary	Number of Participants in Local Tolerability Clinician Injection Site Assessment Categories	The investigator assessed the injection site after the first dose and before the fourth dose for the presence of erythema (None, Mild, Moderate, Severe), pigmentation (None, Hypo, Hyper), Induration (None, Mild, Moderate, Severe), Tenderness (None, Mild, Moderate, Severe) and Temperature (Normal, Warm, Hot). The number of participants in each grade is reported.	After the first and fourth injections in 303, approximately Week 0 and Week 12
Secondary	Number of Participants With Anti-BIIB019 Binding Antibodies (ADAbs) in the 205MS303 Treatment Period	Blood samples were collected for ADAbs and were analyzed using a laboratory test. The number of participants ADAb positive at any post-baseline timepoint is reported.	Up to 4.6 years in the 303 Treatment Period
Secondary	Number of Participants With Anti-BIIB019 Neutralizing Antibodies (Nabs) in the 205MS303 Treatment Period	Blood samples were collected for NAbs and were analyzed using a laboratory test. The number of participants NAb positive at any post-baseline timepoint is reported.	Up to 4.6 years in the 303 Treatment Period
Secondary	Change From 205MS303 Baseline in the Symbol Digit Modalities Test (SDMT) Score in the 205MS303 Treatment Period	SDMT is a screening test for cognitive impairment. Participants are given 90 seconds in which to pair specific numbers with given geometric figures using a key. Scores range from 0 to 110 (best). A positive change from baseline indicates improvement.	Baseline 303, Weeks 144, 168, 192, 240 in 303
Secondary	Change From 205MS301 Baseline in the SDMT Score in the 205MS301-303 Combined Study Period	SDMT is a screening test for cognitive impairment. Participants are given 90 seconds in which to pair specific numbers with given geometric figures using a key. Scores range from 0 to 110 (best). A positive change from baseline indicates improvement.	Baseline 301, Weeks 24, 48, 72, 96, 120, 144 in 301; Weeks 144, 168, 192, 216, 240 in 303
Secondary	Change From Baseline in 3-Second Paced Auditory Serial Addition Test (PASAT 3) Score in the 205MS303 Treatment Period	The PASAT 3 assesses auditory information processing speed. A random series of numbers from 1 to 9, inclusive, are presented and the participant is instructed to consecutively add pairs of numbers so that each number is added to the one that immediately preceded it. In the 3- second PASAT, numbers are presented at a rate of 1 every 3 seconds. The total possible score is the number of correct responses from 0 to 60 (best). A positive change from baseline indicates improvement.	Baseline 303, Weeks 12, 24, 48, 120, 144, 168, 192, 216, 240 in 303
Secondary	Change From Baseline in 3-Second Paced Auditory Serial Addition Test (PASAT 3) Score in the 205MS301-303 Combined Study Period	The PASAT 3 assesses auditory information processing speed. A random series of numbers from 1 to 9, inclusive, are presented and the participant is instructed to consecutively add pairs of numbers so that each number is added to the one that immediately preceded it. In the 3- second PASAT, numbers are presented at a rate of 1 every 3 seconds. The total possible score is the number of correct responses from 0 to 60 (best). A positive change from baseline indicates improvement.	Baseline 301, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 in the 301 study, Baseline 303, Weeks 12, 24, 48, 120, 144,168, 192, 216, 240 in 303 study